Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data

  • At the American College of Cardiology, Lexicon Pharmaceuticals Inc (NASDAQ:LXRXhighlighted a new data analysis from the SCORED Phase 3 trial of sotagliflozin in Type 2 diabetes and kidney disease patients.
  • Sotagliflozin significantly reduced major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo.
  • Also See: Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization.
  • A follow-up analysis of the trial revealed consistent reductions in major adverse cardiovascular events (MACE) in two subgroups —a 21% reduction in MACE in patients with cardiovascular disease and a 26% reduction in MACE in those without CVD.
  • In February, Lexicon pulled back a submission for approval in Type 2 diabetes patients with heart failure. That came on top of an FDA rejection for sotagliflozin in 2019 in Type 1 diabetes.
  • Price Action: LXRX shares are up 3.11% at $2.32 during the premarket session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.